Skip to content
Agentic OS
Menu

Intelligence / Healthtech / De Novo Grants / Cardiosense, Inc.

Approvalsnovel device granted (FDA De Novo)22 May 2026

Cardiosense, Inc.

22 May 2026: Novel device granted (FDA De Novo) · PCWP Analysis Software. Recorded in the openFDA device 510(k) (De Novo decisions).

View the source record

Granted
22 May 2026
Device
PCWP Analysis Software
Specialty
Cardiovascular
Product Code
SIF
Country
United States
Location
Chicago, IL
Submitted
2025-11-17
Reference
DEN250057
What this signal means

A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.

  1. 2 added in the 30 days to 19 Nov 2026.
  2. Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS

Find the decision makers at Cardiosense, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Cardiosense, Inc. in our registers.

More in Cardiovascular

De Novo Grants

See all

Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.